Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma

Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma

Background Metastatic Merkel cell carcinoma (mMCC) is an aggressive neuroendocrine malignancy of the skin with a poor prognosis. Immune checkpoint inhibitors (ICIs) have shown substantial efficacy and favorable safety in clinical trials.Methods Medical records of patients (pts) with mMCC treated wit...

Full description

Bibliographic Details
Main Authors: Grant A McArthur, Alison M Weppler, Andrew Pattison, Paolo De Ieso, Jeanette Raleigh, Athena Hatzimihalis, Shiva Balachander, Jason Callahan, Margaret Chua, Rodney J Hicks, Richard W Tothill
Format: Article
Language:English
Published: BMJ Publishing Group 2020-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e000700.full

Internet

https://jitc.bmj.com/content/8/2/e000700.full

Similar Items